Bioventus, Inc.

How big is Bioventus, Inc.?

As of Jun 18, Bioventus, Inc. has a market capitalization of 521.62 million and reported net sales of 567.70 million with a net profit of -41.17 million for the latest four quarters. Shareholder's funds are 147.94 million, and total assets amount to 727.96 million.

As of Jun 18, Bioventus, Inc. has a market capitalization of 521.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 567.70 million for the latest four quarters, while the net profit for the same period was -41.17 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 147.94 million and total assets amounting to 727.96 million.

What does Bioventus, Inc. do?

Bioventus, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $124 million and a net profit of -$3 million. It has a market cap of $521.62 million and key metrics including a P/E ratio of 345.00 and a debt-to-equity ratio of 2.20.

Overview: <BR>Bioventus, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 124 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 521.62 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 345.00 <BR>Debt Equity: 2.20 <BR>Return on Equity: 1.08% <BR>Price to Book: 3.52<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Bioventus, Inc.?

Is Bioventus, Inc. overvalued or undervalued?

As of May 10, 2022, Bioventus, Inc. is considered a risky investment due to its high valuation metrics and significant underperformance compared to the S&P 500, indicating it may be overvalued.

As of 10 May 2022, the valuation grade for Bioventus, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued given its high P/E ratio of 345, a PEG ratio of 3.00, and an EV to EBITDA of 10.75, which are significantly higher than many of its peers. For instance, Axogen, Inc. has a P/E ratio of -146.35 and an EV to EBITDA of 81.74, while ZimVie, Inc. shows a P/E of -80.95 and an EV to EBITDA of 16.76, both indicating a challenging environment for the sector.<BR><BR>In terms of performance, Bioventus has underperformed compared to the S&P 500, with a year-to-date return of -31.43% versus the index's 12.22%, and a one-year return of -38.41% compared to 17.14% for the S&P 500. This underperformance reinforces the notion that the stock may be overvalued in the current market context.

Is Bioventus, Inc. technically bullish or bearish?

As of August 6, 2025, Bioventus, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -31.43% versus the index's 12.22%.

As of 6 August 2025, the technical trend for Bioventus, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but remains bearish on the monthly. The moving averages indicate a mildly bearish trend on the daily timeframe. Additionally, the KST is mildly bullish weekly but mildly bearish monthly, while the OBV and Dow Theory both reflect a mildly bearish stance on the weekly chart.<BR><BR>In terms of performance, Bioventus has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -31.43% versus the S&P 500's 12.22%, and a one-year return of -38.41% compared to 17.14% for the index.